EMA reviewing Lantus biosimilar

Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said EMA accepted for review an MAA for the partners’ biosimilar insulin glargine to treat Type I and Type II diabetes. The companies said the MAA includes data showing bioequivalence to Lantus insulin glargine from Sanofi (Euronext:SAN; NYSE:SNY), a synthetic sustained-release subcutaneous insulin analog.

Mylan and Biocon partnered in 2013 to develop and commercialize biosimilar versions of insulin analog products (see BioCentury Extra, Feb. 13, 2013)...